Mimedx (MDXG) Cash from Investing Activities (2011 - 2026)
Mimedx (MDXG) reported Cash from Investing Activities of -$5.6 million for Q1 2026, down 1289.66% on a YoY basis from $474255.1 in Q1 2025, and down 1584.18% sequentially from -$335000.0 in Q4 2025.
Mimedx (MDXG) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Mimedx (MDXG) has 16 years of Cash from Investing Activities data on file, last reported at -$5.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 1289.66% year-over-year to -$5.6 million; the trailing twelve-month figure through Mar 2026 stood at -$12.1 million (down 205.73% YoY), and the FY2025 full-year result was -$6.9 million, up 28.14% from the prior year.
- Cash from Investing Activities slipped to -$5.6 million in Q1 2026, from -$335000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $113000.0 in Q3 2024 to a low of -$6.0 million in Q1 2024.
- A 5-year average of -$1.6 million and a median of -$649000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 117.41% in 2024 and sank 4753.1% in 2025, its largest moves.
- Tracing MDXG's Cash from Investing Activities over 5 years: stood at -$1.7 million in 2022, then surged by 71.85% to -$481000.0 in 2023, then tumbled by 475.26% to -$2.8 million in 2024, then surged by 87.89% to -$335000.0 in 2025, then plunged by 1584.18% to -$5.6 million in 2026.
- Business Quant data shows MDXG's Cash from Investing Activities at -$5.6 million in Q1 2026, -$335000.0 in Q4 2025, and -$5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Mimedx | 635.35 Mn | 475.58 Mn | 41.62 Mn | -5.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.64 Mn |
| Mar 31, 2026 | -5.64 Mn |
| Dec 31, 2025 | -335,000.00 |
| Dec 31, 2025 | -335,000.00 |
| Sep 30, 2025 | -5.26 Mn |
| Sep 30, 2025 | -5.26 Mn |
| Jun 30, 2025 | -887,000.00 |
| Jun 30, 2025 | -887,000.00 |
| Mar 31, 2025 | -406,000.00 |
| Mar 31, 2025 | -406,000.00 |
| Dec 31, 2024 | -2.77 Mn |
| Dec 31, 2024 | -2.77 Mn |
| Sep 30, 2024 | 113,000.00 |
| Sep 30, 2024 | 113,000.00 |
| Jun 30, 2024 | -905,000.00 |
| Jun 30, 2024 | -905,000.00 |
| Mar 31, 2024 | -6.02 Mn |
| Mar 31, 2024 | -6.02 Mn |
| Dec 31, 2023 | -481,000.00 |
| Dec 31, 2023 | -481,000.00 |